EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Characterization of the Visceral Antinociceptive Effect of Glial Glutamate Transporter GLT-1 Upregulation by Ceftriaxone

K Roman, M Yang, Robert L Stephens

ISRN Pain · 2013

DOI: 10.1155/2013/726891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ISRN Pain, 2013. Verfasst von K Roman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Cell Biology, The Ohio State University, 304 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: NIDDK NIH HHS, National Natural Science Foundation of China, National Institutes of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent studies demonstrate that glial glutamate transporter-1 (GLT-1) upregulation attenuates visceral nociception. The present work further characterized the effect of ceftriaxone- (CTX-) mediated GLT-1 upregulation on visceral hyperalgesia. Intrathecal pretreatment with dihydrokainate, a selective GLT-1 antagonist, produced a reversal of the antinociceptive response to bladder distension produced by CTX. The hyperalgesic response to urinary bladder distension caused by intravesicular acrolein was also attenuated by CTX treatment as was the enhanced time spent licking of abdominal area due to intravesicular acrolein. Bladder inflammation via cyclophosphamide injections enhanced the nociceptive to bladder distension; cohorts administered CTX and concomitant cyclophosphamide showed reduced hyperalgesic response. Cyclophosphamide-induced bladder hyperalgesia correlated with a significant 22% increase in GluR1 AMPA receptor subunit expression in the membrane fraction of the lumbosacral spinal cord, which was attenuated by CTX coadministration. Finally, neonatal colon insult-induced hyperalgesia caused by intracolonic mustard oil (2%) administration at P9 and P11 was attenuated by CTX. These studies suggest that GLT-1 upregulation (1) attenuates the hyperalgesia caused by bladder irritation/inflammation or by neonatal colonic insult, (2) acts at a spinal site, and (3) may produce antinociceptive effects by attenuating GluR1 membrane trafficking. These findings support further consideration of this FDA-approved drug to treat chronic pelvic pain syndromes.

Autor:innen und Institutionen

  • Department of Physiology and Cell Biology, The Ohio State University, 304 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA.
  • Department of Gastroenterology, Daping Hospital, Third Military Medical University, Chongqing 400042, China.

Förderung

  • NIDDK NIH HHS
  • National Natural Science Foundation of China
  • National Institutes of Health

Zitieren

APA

Roman, K., Yang, M., & Stephens, R. L. (2013). Characterization of the Visceral Antinociceptive Effect of Glial Glutamate Transporter GLT-1 Upregulation by Ceftriaxone. ISRN Pain. https://doi.org/10.1155/2013/726891

Vancouver

Roman K, Yang M, Stephens RL. Characterization of the Visceral Antinociceptive Effect of Glial Glutamate Transporter GLT-1 Upregulation by Ceftriaxone. ISRN Pain. 2013. doi:10.1155/2013/726891

BibTeX
@article{Roman2013,
  author = {Roman, K and Yang, M and Stephens, Robert L},
  title = {Characterization of the Visceral Antinociceptive Effect of Glial Glutamate Transporter GLT-1 Upregulation by Ceftriaxone},
  journal = {ISRN Pain},
  year = {2013},
  doi = {10.1155/2013/726891}
}
Kostenlos starten →